Aims To conduct a cost-effectiveness analysis (CEA) comparing the delivery of brief intervention (BI) with brief treatment (BT) within Screening, Brief Intervention and Referral to Treatment (SBIRT) programs. Design Quasi-experimental differences in observed baseline characteristics between BI and BT patients were adjusted using propensity score techniques. Incremental comparison of costs and health outcomes associated with BI and BT. Setting Health-care settings in four US states participating in Substance Abuse and Mental Health Services Administration SBIRT grant programs.
INTRODUCTION
The physical, psychological and social harms of substance misuse represent an important public health problem. Substance abuse and dependence is recognized widely as a serious and costly societal problem affecting an estimated 22.2 million people, or 8.5% of the US population aged more than 12 years in 2012 [1, 2] . Just as significant are the estimated 22.5 million people who used illicit drugs or drank heavily over the past month but did not meet the clinical guidelines for either abuse or dependence (authors' calculations: Substance Abuse and Mental Health Data Archive-SAMHDA-calculating tool [3] ). Screening and brief intervention (SBI) for alcohol has been shown to be clinically effective at identifying and addressing the needs of people who consume above guidelines for low-risk consumption but who would not be considered dependent [4] [5] [6] [7] [8] ; however, recent studies have shown a lack of effectiveness of SBI targeting drug misuse in primary care settings [9, 10] .
In 2003, the United States Substance Abuse and Mental Health Services Administration (SAMHSA) launched a major initiative-Screening, Brief Intervention and Referral to Treatment (SBIRT)-to address substance misuse of all individuals presenting for care, but not specifically seeking treatment for substance use in medical settings [11] . Since 2003, SAMHSA has funded competitive cooperative agreements with 29 states, one territory and two tribal councils to establish SBIRT services. SBIRT is a public health approach to identifying people who engage in unhealthy substance use behaviors and providing an appropriate level of care to those who need it. By screening for substance use that exceeds recommended guidelines, including use indicative of dependence, SBIRT helps to prevent the onset of more severe consequences [12, 13] .
The SBIRT continuum includes screening, brief intervention (BI), brief treatment (BT) and referral to treatment (RT). The two most widely used tools for screening include the Alcohol Use Disorders Identification Test (AUDIT) [14] for alcohol and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) [15, 16] for alcohol, prescription medicines and illicit drug use.
BI is intended to comprise one to five sessions lasting 5 minutes to 1 hour. It has the goal of educating patients and increasing their motivation to reduce risky behavior. BI is delivered using a motivational interviewing (MI) approach [17] or other recognized method to increase awareness regarding substance use and motivation towards behavioral change. Compared to BI, BT targets patients with higher risk factors and thus should require more resources. BT is intended to comprise five to 12 individual (rather than group) 1-hour sessions. BT and BI share the goal of altering the individual's understanding of factors that influence substance use [18] . BT usually applies a structured approach combining motivational enhancement (MET) [19] and cognitive-behavioral (CBT) [20] therapies. Referral to treatment (RT) helps to address the treatment needs of people at the upper end of the risk continuum, including those dependent upon alcohol or drugs [13] . It includes linkage with appropriate service options, including out-patient programs and in-patient facilities [21] .
In 2008, 5-year SAMHSA SBIRT grants were awarded to four grantees-three states and one tribal organization located in the Southeast, Midwest and Northwest regions of the United States-for the implementation of SBIRT in health-care settings. The most common types of settings were emergency department and trauma centers (ED), and a variety of out-patient hospital clinics and ambulatory clinics, including Federally Qualified Health Centers. Patients presenting to the SBIRT performance sites were screened and intervened concurrently for alcohol consumption, prescription drug abuse and illicit drug use. Generally, patients' first interaction with SBIRT was a pre-screen, which was administered by SBIRT practitioners, general medical staff such as nurses or medical assistants, or self-administered by the patient, depending on the performance site [22] . All SBIRT activities after the pre-screen, including the ASSIST full screen [15, 16] , were performed by a SBIRT practitioner. SBIRT practitioners were non-medical substance abuse or behavioral health specialists (e.g. behavioral counselors, substance abuse counselors, social workers, psychologists and health educators), generally holding a Master's level or higher, and approximately half were certified or licensed in addiction treatment. Patients who screened positive on the ASSIST were slated to receive at least one BI, BT or RT based on screen score, practitioners' judgment and patients' preference. Patients with the greatest severity were referred to specialty substance abuse care [23] .
Observations of SBIRT services delivery by the four grantees indicated that, on average, each BI session lasted 7 minutes and each BT session lasted 45 minutes. Based on service-receipt data, patients assigned to BI received on average 1.2 BI sessions, and patients assigned to BT received on average 0.5 BI sessions and 2.6 BT sessions. Observations and interviews with providers showed that both BI and BT were MI-based, and some programs also adopted MET and CBT [24] . These results show that, in practice, the implementation of the SBIRT components in the third cohort of grantees was very different from the protocol, particularly for BT. The number of BT sessions delivered was well below the intended five to 12 sessions, and in many cases their content was very similar to BI, to the point that some practitioners described BT as a more intense BI.
The effectiveness of more intensive BI (longer contact with the patient and multi-contact) compared to standard BI (one session lasting approximately 5 minutes) has been analyzed, but results were inconclusive. While a recent study suggests that greater effect sizes may be achieved with more intensive BIs [7] , another review found that longer BIs offered a greater reduction in alcohol consumption, but the results were not statistically significant [8] . In addition, although there is ample evidence to support the efficacy and effectiveness of BI for alcohol and other substance use, less attention has focused upon BT as a service within the BT continuum.
SAMHSA is placing a considerable investment on the implementation of SBIRT across the United States. Based on the unknown effect of BT within the SAMHSA SBIRT continuum, and in light of budget constraints, understanding the cost-effectiveness of BT compared to BI is important for policymakers and treatment providers, as they allocate scarce resources among various treatment services [25] [26] [27] . Decision-makers need to understand if the effects of BT justify the additional costs of delivering BT instead of or in addition to BI.
Prior studies have examined the cost-effectiveness of SBI in different medical settings [28] [29] [30] , but no study has considered the cost-effectiveness of BI compared to BT. This study conducts a cost-effectiveness analysis (CEA) to answer an important research question: within the SBIRT continuum, is it worth it to devote extra resources to BT when compared to BI?
This study focuses on SBIRT as implemented in situ, rather than in the artificial environment of a randomized controlled trial (RCT). The analytical design is quasiexperimental, reflecting the fact that the purpose of the grant was to implement SBIRT rather than determine the efficacy of SBIRT components. The design exploits the fact that many patients who received only BI services ('BI patients') were similar in their observed characteristics to those who received BT ('BT patients'). The many reasons for these similarities include patient and provider characteristics. Patients whose screening risk score is just above the higher level of service (BT) cut-off have similar risk levels to those whose risk score is just below the cut-off. Additionally, some patients who would have been candidates for BT may have only been willing to participate in a BI session. Providers might also have a preference for BT or BI, depending on their clinical judgment and time availability. A statistical method, propensity scoring, is used to adjust for differences in observed characteristics between the groups. The costs of SBIRT delivery to BI and BT patients are compared incrementally to the differences in several measures of alcohol and illicit drug use.
METHODS

Data
As a condition of the grant, participating performance sites were required to complete the Government Performance Results Act (GPRA) survey for each of their patients [31] . The GPRA survey serves as the source of patient characteristics, number of BI and BT sessions received and patient outcomes. Because grantees were only required to complete a portion of the GPRA survey with BI patients, patient characteristics included in the current study are limited to gender, age, race/ethnicity and substance use status. GPRA data were collected at baseline, at discharge from the program and as part of a 6-month follow-up. SAMHSA required collection of 6-month follow-up data on 10% of screen positives. The discharge survey captured which services a patient received and the number of sessions, and was used to categorize screen-positive patients as BI or BT patients. BI patients were those who received at least one BI and no BT, and BT patients were those who received at least one BT session with or without BI.
Health outcomes were measured by the change from baseline to 6-month follow-up in the following past 30-day substance use measures: proportion using alcohol, proportion using alcohol to intoxication, days of alcohol use, days of alcohol use to intoxication, proportion using drugs and days using drugs.
The unit costs of each SBIRT component were taken from the companion cost study [32] . The study used data from 26 performance sites across the four grantees to estimate unit costs of SBIRT service components from the perspective of service providers. Unit costs were the sum of labor, materials and space costs. A time-and-motion approach, where the time of each SBIRT activity was measured accurately, was used to estimate the time practitioners took to deliver SBIRT services [24, 33] . This time was used to value labor costs. Non-labor costs comprised a relatively small portion of the unit costs. For each individual, the unit cost of a screen, BI and BT was multiplied by the number of sessions received. For observations with no information on setting, the average of ED and out-patient unit cost was used. In ED the unit costs of a screen, BI and BT were $6.59, $10.48 and $22.63, respectively; in out-patient unit costs were $3.98, $7.81 and $27.94; and for observations with no information on setting unit costs were $5.29, $9.15 and $25.29. All costs are in 2012 $US.
Study design
The study uses a quasi-experimental design to compare BI and BT. Because people are not assigned randomly to BI and BT, comparisons between the two service components should correct for potential confounds, particularly those who are correlated both with assignment to BI or BT and the outcomes [34] .
Propensity score methods were applied to adjust statistically the BI and BT group-observable characteristics [35] [36] [37] [38] [39] [40] [41] . The method involves estimating with a multivariate regression the probability that each observation is assigned to BT; that probability is the propensity score. The propensity score is then used to adjust or weight comparisons between members of the two groups based on the degree to which each individual patient in the BI group has a similar score to individual patients in the BT group.
Sample
There were 489 396 intake records in GPRA; of those, 2575 were eligible for follow-up data collection, and 1906 had 6-month follow-up data. Observations were then excluded if they could not be identified as either BI or BT patients (i.e. were missing discharge data), were missing data on baseline demographics or substance use or were under age 18 or screened outside a medical facility (e.g. health fair). These exclusions formed an intermediate analysis sample of 976, comprising 878 BI patients and 98 BT patients. The final analytical sample for the CEA also excluded eight patients assigned to BT for whom no common support could be found in the propensity score adjustment. When compared to the 90 BT patients included in the CEA, the group of eight patients excluded had a higher proportion of illicit drug users, in particular opiate use. Table 1 describes the baseline characteristics of the analytical sample. The estimates show significant differences (at the 95% level) between the groups in days of alcohol use to intoxication and the proportions of illicit drug users, cocaine users and opiate users.
Analysis
Propensity score and balance assessment. To determine the statistical specification of the propensity score, a stepwise routine with backward selection was used. Multiple interaction terms and polynomial expansions were included to improve model fit and reduce unexplained variation. A specification with a very large number of terms was reduced iteratively until only covariates with P-values less than 0.25 remained in the model. Following the stepwise routine, the 26 covariates used in the propensity score model included measures of gender, race, age, grantee, calendar year of intake, setting, RT receipt and alcohol and illicit drug use.
To compare the adjusted groups on outcomes we used kernel matching with the Epanechnikov kernel, which estimates the counterfactual mean for the comparisons using a local linear regression estimator [42] . With kernel matching, all patients in the treated (BT) group are matched with a weighted average of all patients in the comparison (BI) group. Weights are inversely proportional to the distance between the propensity scores of treated and comparisons. The matching procedure used Stata's psmatch2 command with a logit specification to estimate the individual probability of being exposed to the BT treatment conditional on the baseline covariates included in the logit model [43, 44] .
Standardized differences were estimated to assess balance between the BI and BT groups [40, 45] . The standardized difference is preferable to hypothesis testing because balance is a characteristic of the observed sample, not a population characteristic [46, 47] . Relative balance refers to whether the standardized difference is reduced by matching. Ideal absolute balance is achieved if the standardized difference is less than or equal to 0.1, and generally acceptable if the difference is below 0.2 [40, 45, 48] . Figure 1 shows that matching reduced the standardized difference for most variables and achieved adequate balance for all variables. Exceptions where relative balance deteriorates include the out-patient setting indicator, gender, age, some demographic interactions and days of marijuana use. All measures for which relative balance is not achieved are balanced in an absolute sense. The out-patient indicator, the age × gender interaction and some measures of alcohol and drug use have standardized differences slightly above 0.1 but well below 0.2 after balancing. Lower balance on a particular variable does not imply lack of overall balance between the treatment and comparison groups. In fact, the standardized difference of the median covariate fell from 0.120 without propensity score adjustment to 0.055 after propensity score adjustment, demonstrating a large overall improvement in balance.
Cost-effectiveness analysis
The CEA compared the costs and effects (health outcomes) of the two SBIRT components, BT and BI, to determine the value for money of providing BT instead of BI. The CEA was performed for each of the six outcomes separately. All measures that are proportions are interpreted as individual probabilities; for example, the proportion of patients using alcohol is used to represent the probability an individual uses alcohol. To conduct the CEA, BI and BT were first ranked by cost and then assessed for dominance, meaning that one is both more effective and less costly than the other. If neither strategy was dominant, an incremental cost-effectiveness ratio (ICER) was then computed to estimate the additional cost required to achieve one additional unit of outcome. The ICER is the difference in mean costs (C) divided by the difference in mean effectiveness (E), (C BT À C BI )/(E BT À E BI ) for BT and BI. Finally, the ICER is compared to the decision-maker's willingness to pay (WTP) for a 1-unit improvement in the outcome. The more expensive strategy is cost-effective if the ICER is less than the WTP [49, 50] . After propensity score adjustment, uncertainty in both costs and outcomes was taken into account by bootstrapping individual-level costs and outcomes with replacement over 2500 draws. Cost-effectiveness acceptability curves (CEACs) were computed and represented graphically to show the probability that one strategy is more cost-effective than the other, based on the decisionmakers' WTP for an additional reduction in consumption [49, [51] [52] [53] .
RESULTS
The estimated cost of BT, at $75.54, was more than four times the estimated cost of BI, at $16.32, a difference that was statistically significant at the 5% level. The reason for the differential is that BT patients received on average 0.5 BI sessions and 2.6 BT sessions, whereas BI patients received on average 1.2 BI sessions. Table 2 presents the effectiveness of BT relative to BI for each outcome, after propensity score adjustment. To compute the impact on effectiveness, the mean difference between the outcome at baseline and at 6 months was computed (the pre-post difference) for both BT and BI; Both BT and BI improved substance use measures. However, BI was more effective than BT for five of the six outcomes analyzed. Only for the probability of alcohol use did BT improve the outcome relative to BI (33 versus 27% reduction). For all six outcomes, the difference between BT and BI was not statistically significant at conventional levels. The ICER for any alcohol use was $8.90. Thus, relative to BI, BT would cost $8.90 more to achieve a 1 percentage point reduction in the probability of using any alcohol. BI dominated BT for the five remaining outcomes (i.e. BI was cheaper and at least equally as effective). Figure 2 presents the CEAC for the probability of any alcohol use. The figure shows that if the decision maker was willing to pay more than $8.90 per person (the ICER) for a 1 percentage point reduction in the probability of consuming any alcohol, BT would be more cost-effective than BI. As the decision-makers' WTP increases, the more costly and effective strategy is preferred.
However, regardless of how much the decision-maker is willing to pay, the highest probability that BT is more costeffective than BI is approximately 80%. This indicates that there is considerable uncertainty that BT leads to a higher reduction in the probability of alcohol use and that there is no WTP for which the decision-maker can be 95% confident that the economic value of BI and BT differ [53] .
DISCUSSION
This study conducted the first cost-effectiveness analysis of BT versus BI in health-care settings and, unlike most previous studies, accounted for both unhealthy alcohol use and illicit drug use. The SBIRT program in the United States explicitly recommends the delivery of BT to those with riskier levels of alcohol and drug use. This study assessed whether it is worth devoting extra resources to BT compared to BI. Using administrative GPRA data combined with primary data on costs, propensity score methods were applied to compare BI and BT patients in terms of costs and six health outcomes: probability of using alcohol, probability of using alcohol to intoxication, days of alcohol use, days of alcohol use to intoxication, probability of using drugs and days using drugs.
Two findings provide important nuances to the general conclusions. First, the finding supporting BT to be costeffective (depending on the decision-maker's WTP) holds only for alcohol, and not for illicit drugs. Secondly, the Based on 2500 replications with replacement after propensity score adjustment. No estimate of the impact on effectiveness is significant at the 10% level. BI = brief intervention; BT = brief treatment. Figure 2 Cost-effectiveness acceptability curve for the probability of any alcohol use difference in effectiveness between BI and BT was not statistically significant for any outcome; this finding is consistent with studies comparing BI with varying levels of intensity [8] . BT appears to be more cost-effective than BI for reducing the probability of using alcohol, so long as the decision-maker is willing to pay $8.90 for a 1 percentage point reduction in that probability. The question of what value of WTP should be applied to each outcome is beyond the scope of this study. It will probably depend upon the decision-maker and the decision-making jurisdictions [53, 54] . For the other five outcomes, the results indicated that BT costs more and is no more effective than BI, i.e. BI dominated BT.
Taking into account the results of the six outcomes analyzed, our study raises doubts as to whether BT as implemented should be included as well as BI. Results suggest one specific circumstance under which BT might be preferable to BI, and that is if policymakers place a higher value on abstinence from alcohol than on a reduction in the intensity of consumption. Attaining abstinence is usually the objective of specialty substance abuse treatment, which is usually delivered to patients with greater disease severity than the population of this study. It is possible that the more intense psychosocial component of BT drives the increased effectiveness of BT for abstinence-based outcomes. However, the higher effectiveness of BT for this one outcome is associated with considerable uncertainty. Because both BI and BT improve all outcomes, BT may not appear to be a good use of resources. Providers should, of course, choose to offer the most appropriate services given the circumstances and preferences. The results of this study helps with this decision by providing evidence that offering BT instead of or in addition to BI would be associated with a higher cost that might not be justifiable by better health outcomes.
Our study faces at least three limitations. First, the analysis is potentially biased by differences across the BI and BT groups because individuals were not assigned randomly to the two conditions. Although using propensity score methods balanced the observed covariates at baseline, it cannot guarantee balance across unobserved confounding factors [39] . In particular, the study did not provide data on patient-level factors that might influence the effectiveness of BI and BT (e.g. willingness to change) and also have an impact upon the clinician's decision to use either BI or BT. Secondly, the study used data from an evaluation of SBIRT as implemented in situ, rather than a RCT with a prospective design. Intervention delivery did not follow protocols designed specifically to answer effectiveness and cost-effectiveness questions. Similarly, the number of observations necessary to provide statistical power were not defined a priori, the number of patients receiving BT was small and the number of BT sessions received was considerably lower than intended. Thirdly, the study used a range of health outcome measures that might not capture the full benefits of SBIRT. The four alcohol measures available in the data lack information on amount consumed in each occasion and number of occasions, thereby not providing full information on drinking patterns. Also, instead of using six separate outcome measures, ideally a composite outcome measure would be used. The outcome measures used do not allow comparison to other conditions that compete for the same resources. To address this concern, further studies may consider including outcome measures that extend to other health states, such as quality-adjusted life years [40] .
Despite the limitations, the current study makes several contributions to the literature on SBIRT. Few economic evaluations assess SBI as implemented, outside a RCT. Because policy is implemented outside a controlled experiment, policymakers are well served when presented with evidence both from RCTs and studies such as the current study that are conducted in situ. The current study is also important in light of the fact that the SBIRT program is one of the biggest single sources of supporting SBI services in the United States. When allocating scarce health-care resources, it is important to understand the relative improvement in outcome and cost incurred with key SBIRT services. In addition to completing subgroup and sensitivity analyses, future work should further explore potential moderators of the cost-effectiveness of BT relative to BI and attempt to replicate the findings with other samples. Additionally, the methods here could be used to compare other individual service components, such as a screen-only to a pre-screen combined with a screen.
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